Webinars Archives

← ALL VIDEOS

Webinars

We are Invivoscribe – Company Overview

Invivoscribe Marketing2023-02-17T20:45:18-08:00December 30th, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

Lab Secrets: The Potential for NGS-based MRD Testing for Acute Lymphoblastic Leukemia – The Austin Experience

Invivoscribe Marketing2022-11-18T23:16:58-08:00November 15th, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

Development and Implementation of an Automated and Highly Accurate Reporting Process for NGS-based Clonality Testing

wmm2023-01-16T21:30:16-08:00November 2nd, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

High-Throughput Sequencing of TCR Gene Rearrangements as a Useful Tool for Identifying and Tracking Minimal/Measurable Residual Disease (MRD) in Lymphoid Malignancies

wmm2023-01-16T21:27:56-08:00November 2nd, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

NGS-based Clinical Assessment of B- and T-cell Clonality and MRD Determination

wmm2022-10-27T04:25:21-07:00October 26th, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

A Comprehensive Solution for AML Precision Diagnostics

Invivoscribe Marketing2022-08-02T14:52:04-07:00July 20th, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

Global Standardization of Flow Cytometry Results with AI Systems

Invivoscribe Marketing2022-05-25T03:00:57-07:00December 8th, 2021|2021 Videos, 2021 Webinars, Featured Videos, Videos, Webinars|

Watch video

Explore the Benefits, Considerations, and Utility of NGS B- and T-cell Clonality

Invivoscribe Marketing2022-05-25T03:00:57-07:00October 28th, 2021|2021 Videos, 2021 Webinars, Featured Videos, Videos, Webinars|

Watch video

A Streamlined Laboratory Workflow for Controlling Antibody and Reagent Lots on a 12C Flow Cytometry System

Invivoscribe Marketing2022-05-25T03:00:58-07:00July 15th, 2021|2021 Videos, 2021 Webinars, Featured Videos, Videos, Webinars|

Watch video

Complementary Value of MRD Assessments by NGS and MFC for the Study of Hematologic Malignancies

Invivoscribe Marketing2022-05-25T03:00:58-07:00December 1st, 2020|2020 Videos, 2020 Webinars, Videos, Webinars|

Watch video

Clinical Utility of NGS in Lymphoid Malignancies

Invivoscribe Marketing2022-05-25T03:00:59-07:00February 27th, 2020|2020 Videos, 2020 Webinars, Videos, Webinars|

Watch video

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

We are Invivoscribe – Company Overview

Lab Secrets: The Potential for NGS-based MRD Testing for Acute Lymphoblastic Leukemia – The Austin Experience

Development and Implementation of an Automated and Highly Accurate Reporting Process for NGS-based Clonality Testing

High-Throughput Sequencing of TCR Gene Rearrangements as a Useful Tool for Identifying and Tracking Minimal/Measurable Residual Disease (MRD) in Lymphoid Malignancies

NGS-based Clinical Assessment of B- and T-cell Clonality and MRD Determination

A Comprehensive Solution for AML Precision Diagnostics

Global Standardization of Flow Cytometry Results with AI Systems

Explore the Benefits, Considerations, and Utility of NGS B- and T-cell Clonality

A Streamlined Laboratory Workflow for Controlling Antibody and Reagent Lots on a 12C Flow Cytometry System

Complementary Value of MRD Assessments by NGS and MFC for the Study of Hematologic Malignancies

Clinical Utility of NGS in Lymphoid Malignancies

Title

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021 Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

Title

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing